A.Menarini Diagnostics (Menarini) is set to commercially introduce its sample-to-result, fully-automated molecular diagnostics platform, PRIME MDx platform.
The all-in-one platform will be officially displayed at the ongoing WorldLab EuroMedLab in Rome, Italy. It is designed to process several testing portfolios using real-time polymerase chain reaction (PCR).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The system will be introduced to the market with two types of tests, including one for viral upper respiratory tract infections and another for viral transplant infections on a range of sample matrices.
Menarini is currently working on developing more testing panels.
Menarini Group diagnostics division global head and general manager Fabio Piazzalunga said: “We are proud to bring this innovative, all-in-one, molecular diagnostics solution to the market, which will allow us to address the needs of medium-to-high throughput laboratories internationally and strengthen the position of A. Menarini Diagnostics in the molecular space.”
PRIME MDx employs pre-filled plates along with a universal extraction solution to process various types of samples.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe platform can run up to five different assays per sample for up to 240 samples a day. The artificial intelligence software enhances customer experience throughout the entire process, from sample loading to interpreting results.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group. Menarini is involved in the development of high-tech diagnostics systems and reagents to meet the diagnostics requirements of healthcare professionals.
The company operates under two business units, namely the diabetes care and laboratory.
